Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · Real-Time Price · USD
8.28
-0.38 (-4.39%)
At close: Mar 28, 2025, 4:00 PM
8.38
+0.10 (1.26%)
After-hours: Mar 28, 2025, 5:12 PM EDT
Sage Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Sage Therapeutics stock have an average target of 9.88, with a low estimate of 4.00 and a high estimate of 26. The average target predicts an increase of 19.32% from the current stock price of 8.28.
Analyst Consensus: Hold
* Price targets were last updated on Feb 12, 2025.
Analyst Ratings
The average analyst rating for Sage Therapeutics stock from 19 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 15 | 16 | 15 | 15 | 15 | 14 |
| Sell | 2 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 20 | 20 | 19 | 20 | 20 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $14 → $12 | Buy | Maintains | $14 → $12 | +44.93% | Feb 12, 2025 |
| Wedbush | Wedbush | Hold Reiterates $6 | Hold | Reiterates | $6 | -27.54% | Feb 12, 2025 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $9 → $8 | Hold | Maintains | $9 → $8 | -3.38% | Feb 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $14 → $12 | Hold | Reiterates | $14 → $12 | +44.93% | Feb 12, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 12, 2025 |
Financial Forecast
Revenue This Year
82.65M
from 41.24M
Increased by 100.39%
Revenue Next Year
141.21M
from 82.65M
Increased by 70.86%
EPS This Year
-3.55
from -6.59
EPS Next Year
-2.77
from -3.55
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 137.8M | 550.2M | 237.5M | ||
| Avg | 82.6M | 141.2M | 151.5M | ||
| Low | 50.8M | 65.9M | 109.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 234.0% | 565.7% | 68.2% | ||
| Avg | 100.4% | 70.9% | 7.3% | ||
| Low | 23.3% | -20.3% | -22.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.74 | -1.53 | -0.38 | ||
| Avg | -3.55 | -2.77 | -1.58 | ||
| Low | -4.69 | -4.22 | -2.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.